Special Features

American Society of Nephrology Quiz and Questionnaire 2014: Glomerular Diseases

Andrew S. Bomback, Mark A. Perazella and Michael J. Choi
CJASN April 2015, 10 (4) 716-722; DOI: https://doi.org/10.2215/CJN.11821214

Abstract

The Nephrology Quiz and Questionnaire remains an extremely popular session for attendees of the Annual Kidney Week Meeting of the American Society of Nephrology. Once again, the conference hall was overflowing with audience members and eager quiz participants. Topics covered by the expert discussants included electrolyte and acid-base disorders, glomerular disease, ESRD/dialysis, and transplantation. Complex cases representing each of these categories along with single best answer questions were prepared and submitted by the panel of experts. Before the meeting, program directors of United States nephrology training programs and nephrology fellows answered the questions through an internet-based questionnaire. During the live session, members of the audience tested their knowledge and judgment on a series of case-oriented questions that were prepared and discussed by the experts. They compared their answers in real time using audience response devices with the answers of the nephrology fellows and training program directors. The correct and incorrect answers were then discussed after the audience responses, and the results of the questionnaire were displayed. As always, the audience, lecturers, and moderators enjoyed this educational session. This article recapitulates the session and reproduces its educational value for the readers of CJASN. Enjoy the clinical cases and expert discussions.

Introduction: Mark A. Perazella and Michael J. Choi (Comoderators)

For most American Society of Nephrology (ASN) Kidney Week attendees, case-based clinical nephrology talks are the most exciting venues of the meeting. The Nephrology Quiz and Questionnaire (NQ&Q) is the essence of clinical nephrology and represents what drew many of us into the field of nephrology. This year’s NQ&Q in Philadelphia, with full-house attendance, was no exception. The discussants prepared vignettes of puzzling cases, which illustrated some topical, challenging, or controversial aspect of the diagnosis or management of various areas of nephrology. These eight interesting cases were presented and eloquently discussed by our four expert ASN faculty. Subsequently, each discussant prepared a manuscript summarizing his or her discussion of the cases.

In this NQ&Q, Andrew S. Bomback presents his two challenging cases of glomerular disease. The audience responses are reviewed along with the responses of the training program directors and nephrology fellows obtained from an online questionnaire before the meeting. Andrew S. Bomback reviews essential clinical, laboratory, and renal pathology data in the two cases. He then walks the reader through the diagnosis, discusses key points in the workup, and reviews the appropriate management of these challenging glomerular disorders. We hope that this distillate from Philadelphia will serve CJASN readers well and provide fresh insights into the complexity and vibrancy of clinical nephrology for those who were unable to attend the meeting.

Case 1: Andrew S. Bomback (Discussant)

A 68-year-old woman first noticed bilateral lower extremity edema in November of 2013. She reduced her sodium intake and a week later saw her primary care physician who, in working up the edema, sent her for a urinalysis that showed 3+ proteinuria and no hematuria. Previous blood and urine tests, done in June of 2013 as part of a routine yearly visit, had been unremarkable, including no detectable proteinuria.

She was referred to a nephrologist in December of 2013. At that visit, she reported no symptoms other than edema, which persisted in both lower extremities to the ankles. Specifically, she denied fevers, anorexia, weight loss, night sweats, rash, joint pain, or change in urine color. Her past medical history included 50 pack-years of cigarette smoking with ongoing tobacco abuse, osteoarthritis, and hyperlipidemia. The only medications that she was taking at this time were an over the counter fish oil preparation and acetaminophen as needed for pain. Her family history was negative for renal disease, but her mother had died of leukemia and her sister had died of uterine cancer.

Her vital signs (including BP) were in normal range, and her physical examination was notable only for 1-mm pitting edema to the ankles. Laboratory workup revealed 10 g/d proteinuria on 24-hour collection, creatinine of 0.7 mg/dl, total cholesterol of 350 mg/dl, and albumin of 2.6 g/dl. The following tests were either negative or in the normal range: serum protein electrophoresis, urine protein electrophoresis, antinuclear antibody, C3 and C4, hepatitis B and C, rapid plasma reagin, and myeloperoxidase (MPO) and PR3 ANCA. Renal ultrasound was unremarkable, including no evidence of renal vein thrombosis, and ultrasound of the legs showed no deep venous thrombosis. She was started on lisinopril, atorvastatin, and furosemide. A renal biopsy was performed in January of 2014, and the results (light microscopy, immunofluorescence [IF] microscopy, and electron microscopy) are shown in Figure 1.

Figure 1.
Figure 1.

Kidney biopsy for the patient in case 1. (A) Spike formation between subepithelial immune complex deposits (Jones methenamine silver stain). (B) Dominant granular staining for IgG on immunofluorescence, with similar staining for κ- and λ-light chains. (C) Subepithelial electron dense deposits and intervening spikes of glomerular basement membrane material on electron microscopy. Magnification, ×400 in A and B; ×8000 in C. Reprinted from Glen Markowitz, with permission.

Question 1A

What is the lesion noted on light, IF, and electron microscopy?

  1. Minimal change disease

  2. Membranoproliferative GN

  3. Membranous nephropathy (MN)

  4. FSGS

  5. Amyloidosis

Discussion of Question 1A

The biopsy shows findings of MN (choice C is correct) (Figure 2). On light microscopy, the major abnormality is thickening of the glomerular basement membranes (GBMs) caused by the presence of spike formation between subepithelial immune complex deposits, which is most easily seen on the Jones methenamine silver stain (Figure 1A). IF microscopy shows dominant granular staining for IgG (e.g., 3+) (Figure 1B) with similar staining for κ- and λ-light chains along with granular staining for C3 of lower intensity (e.g., 1+). On electron microscopy (Figure 1C), subepithelial electron dense deposits and intervening spikes of GBM material are the hallmark findings of MN.

Figure 2.
Figure 2.

Answer for case 1, question 1A: What is the lesion noted on light, immunofluorescence, and electron microscopy? The correct answer is C. TPD, Training Program Directors.

Question 1B

What is the most appropriate next step in managing this patient?

  1. Request serologic testing for anti–M-type phospholipase A2 receptor (anti-PLA2R) antibodies

  2. Request IF staining of the biopsy for anti-PLA2R antibodies

  3. Start prophylactic anticoagulation with warfarin

  4. Arrange age– and risk factor–appropriate cancer screening

  5. Recommend first-line immunosuppressive therapy of steroids+alkylating agent

Discussion of Question 1B

This 68-year-old woman with newly diagnosed MN has a past medical history notable for 50 pack-years of smoking and a family history notable for malignancies in her mother and sister; she should be sent for age– and risk factor–appropriate cancer screening (choice D is correct) (Figure 3), which would include Pap smear, mammogram, colonoscopy, and noncontrast computed tomography scan of the chest. The initial step in managing a patient with newly diagnosed MN is to evaluate for secondary forms of the disease, which account for approximately 25% of patients (1,2). This evaluation is often done in the prebiopsy screening laboratory tests (e.g., positive hepatitis B serologies suggesting a viral-associated MN), and it is a component of the biopsy read (e.g., IF pattern of full-house staining indicating membranous lupus nephritis). Cancer screening is particularly important in evaluating secondary forms of MN in patients over the age of 65 years old, because up to 25% of such patients will have a malignancy discovered within 1 year of diagnosis (3). Tobacco abuse is another important risk factor for malignancy-associated MN (1,3).

Figure 3.
Figure 3.

Answer for case 1, question 1B: What is the most appropriate next step in managing this patient? The correct answer is D.

In primary MN, circulating antibodies permeate the GBM and in the subepithelial space form immune complexes with antigens on podocyte membranes. Recently, the PLA2R was identified as the specific podocyte antigen responsible for eliciting immune complex formation with circulating antibodies. Anti-PLA2R antibodies are detected in approximately 75% of patients with primary (formerly termed idiopathic) MN across many ethnicities but are very rare in lupus-, hepatitis-, and tumor-associated MN, indicating alternative pathogenesis in secondary MN (4,5). Additional podocyte autoantigens—mitochondrial superoxide dismutase 2, aldose reductase, α-enolase, neutral endopeptidase, and most recently, thrombospondin type 1 domain–containing 7A (6–8)—have been described, potentially filling in the missing gaps in PLA2R antibody–negative disease. A genome-wide association study of primary MN conducted in three European case-control cohorts identified impressively strong associations with loci on chromosomes 6p21 (HLA-DQA1) and 2q24 (PLA2R1) (9), suggesting that genetic variants might influence the immunogenicity of the antigen (PLA2R), resulting in production of anti-PLA2R autoantibodies. These breakthroughs have established MN as a disease of autoantibodies and made the term idiopathic essentially defunct (10).

It is, therefore, tempting to use anti-PLA2R testing, available as both a serologic assay (ELISA and/or indirect immunofluorescence) and an indirect IF stain for kidney biopsy tissue (11,12), to differentiate primary from secondary forms of MN (choices A and B). However, although this type of profiling may, indeed, promise where the field is headed (13), the approach has yet to be validated in sufficiently large patient samples with sufficient longitudinal follow-up to replace the more traditional methods of screening for malignant, autoimmune, infectious, and medication-associated causes of MN. Furthermore, the sensitivity and specificity of this testing for primary MN remain to be defined across all populations. The original report by Beck et al. (4) suggested a sensitivity of approximately 75% and a specificity of 100% using a serologic assay; however, subsequent reports have suggested a higher sensitivity combining serum and biopsy testing for anti-PLA2R antibodies (11), whereas other studies have reported a low rate of detection of anti-PLA2R antibodies in patients with MN with comorbidities typically associated with secondary forms of the disease, including hepatitis C, sarcoidosis, malignancy, and lupus (5,14). Therefore, the most conservative approach is to interpret a positive anti–PLA2R antibody test (whether by serum or biopsy staining) as highly consistent with primary MN; conversely, a negative anti–PLA2R antibody test denotes either a secondary form of MN or the roughly 20%–25% of primary patients who associate with a different autoantibody.

Nephrotic syndrome is a hypercoagulable state caused by a number of etiologic factors, including urinary loss of low molecular weight anticoagulants (antithrombin III and protein S) and fibrinolytics (plasminogen), hepatic overproduction of proteins in response to hypoalbuminemia of procoagulants (such as factor V, factor VIII, and fibrinogen), and increased levels of free arachidonic acid (again, in response to hypoalbuminemia), leading to increased synthesis of platelet proaggregants (e.g., thromboxane A2) (15). Of all of the nephrotic syndrome etiologies, for reasons heretofore unexplained, MN is associated with the greatest risk for clot, with some series citing up to a 35% lifetime risk for clot for patients with MN (16,17). In the largest cohort of patients with MN studied to date combining United States (n=412) and Canadian (n=486) patients, Lionaki et al. (17) showed that the risk of thrombotic events in MN increased significantly when serum albumin levels fall below 2.8 g/dl. Therefore, this patient with MN and a serum albumin of 2.6 g/dl would be considered high risk for a clotting complication, but there is no consensus agreement on whether such patients should be offered prophylactic anticoagulation (choice C). Lee et al. (18), using the same combined cohort of United States and Canadian patients, recently created a Markov decision model to evaluate the potential benefit of prophylactic anticoagulation (venous thromboembolic events prevented) relative to the risk of such therapy (major bleeds) in patients with MN (an online version of this model is available at www.gntools.com). The model is intended as a tool for clinical decision-making about prophylactic anticoagulation and influenced by both the nephrologist’s and the patient’s acceptable benefit-to-risk ratio. Prophylactic anticoagulation may not require warfarin on the basis of a retrospective analysis published by Medjeral-Thomas et al. (19), in which 143 patients with nephrotic syndrome (41% MN, 31% minimal change disease, and 28% FSGS) were treated with an anticoagulation regimen on the basis of serum albumin. Patients with albumin <2.0 g/dl received prophylactic-dose low molecular weight heparin or low-dose warfarin; patients with albumin levels of 2.0–3.0 g/dl received aspirin at 75 mg daily. During the 5 years of study, no clinical thromboembolic events occurred in patients established on prophylaxis for at least 1 week. Hence, aspirin may be a viable alternative to warfarin for this patient.

Finally, although choice E proposes an appropriate first-line immunosuppressive therapy of steroids plus an alkylating agent, at the time of biopsy diagnosis, this patient was only 2 months into the course of her disease (if we date onset at the first appearance of edema). Given the approximately 30% chance of spontaneous remission seen in MN (20), most guidelines recommend a conservative watch-and-wait approach for the first 6 months in patients with MN without renal failure or other complications of nephrotic syndrome (e.g., a thrombotic event) (21,22). Therefore, after ruling out secondary causes of MN, a regimen of steroids and an alkylating agent would potentially be recommended to this patient if her proteinuria remained in nephrotic range without evidence of a decline 5 months after her biopsy (6 months after her initial presentation). In this patient, however, her proteinuria had declined to 2200 mg/d, and her albumin had risen to 3.2 g/dl by that point, suggesting spontaneous partial remission of disease and no indication for immunosuppression.

Case 2: Andrew S. Bomback (Discussant)

An 83-year-old man, who still works part-time as a realtor and plays doubles tennis twice a week, presented to his primary care physician concerned that he had the flu. He reported chills, poor appetite, and “just not feeling like myself” for the last week. He was ill-appearing, and his examination was notable for lack of fever, hypertension (BP of 155/95 mmHg), and trace lower extremity edema. He was sent for blood work and a chest x-ray; 4 hours later, when the serum creatinine returned at 2.9 mg/dl (by comparison, the level had been 0.9 mg/dl when last checked 3 months earlier), his primary care physician sent him into the emergency room for additional evaluation.

Repeat laboratory tests in the emergency room confirmed AKI (creatinine of 3.1 mg/dl), and urinalysis showed 3+ blood and 2+ protein. His complete blood count was within normal limits. His chest x-ray showed no acute infiltrates. A nephrologist saw him in the emergency room and sent off a panel of diagnostic tests, including serum protein electrophoresis, urine protein electrophoresis, κ:λ-free light chains, anti-GBM antibodies, MPO and PR3 ANCA, antinuclear antibody, C3, C4, hepatitis B and C, HIV, and IgG/IgA/IgM levels. Empirical fluid resuscitation was recommended with normal saline in a 1-L bolus followed by 1 ml/kg per hour. Laboratory tests repeated the following morning showed creatinine of 3.2 mg/dl with persistent hematuria and proteinuria. With the serologic workup still pending, the patient was sent for a renal biopsy in the afternoon.

Question 2A

What is the most likely diagnosis on this biopsy?

  1. Anti-GBM GN

  2. Myeloma cast nephropathy

  3. Pauci-immune necrotizing and crescentic GN, ANCA associated

  4. Crescentic IgA nephropathy

  5. Proliferative lupus nephritis

Discussion of Question 2A

The patient’s clinical picture suggests a rapidly progressive GN (RPGN), with an acute and steep rise in creatinine accompanied by hematuria and proteinuria. The differential diagnosis for RPGN is classically divided into three potential IF findings: pauci-immune staining (e.g., ANCA-mediated GN), linear staining (e.g., anti-GBM nephritis), and granular staining (e.g., lupus nephritis). Pauci-immune, ANCA-associated GN is the most likely RPGN diagnosis in all adults, and the likelihood of this diagnosis rises significantly with age (choice C is correct) (Figure 4). In a series of 235 patients ages ≥80 years old who underwent kidney biopsy over a 44-month period, pauci-immune GN was the most common diagnosis (detected in 19% of patients). This percentage rose to 33% in the subgroup biopsied specifically for the indication of AKI (23). A multicenter review of elderly patients (defined as age ≥60 years old; n=1064) and very elderly patients (defined as age ≥80 years old; n=185) biopsied for AKI reported similar prevalence rates for pauci-immune GN of 33% and 31%, respectively (24).

Figure 4.
Figure 4.

Answer for case 2, question 2A: What is the most likely diagnosis on this biopsy? The correct answer is C.

In this patient, as expected, the biopsy showed a pauci–immune necrotizing and crescentic GN (Figure 5). His serologic workup subsequently returned positive for MPO ANCA (titer >100 arbitrary unit/ml) and negative for PR3 ANCA antibodies. Pulmonary consult deemed bronchoscopy workup for alveolar hemorrhage unnecessary given no history of dyspnea or hemoptysis, appropriate oxygenation on pulse oximetry and arterial blood gas, unremarkable chest x-ray, and no elevations in diffusing capacity for carbon monoxide.

Figure 5.
Figure 5.

Kidney biopsy for the patient in case 2. (A) Light microscopy reveals a crescentic GN, and (B) immunofluorescence is notable for pauci-immune staining. Magnification, ×400. Reprinted from Glen Markowitz, with permission.

Question 2B

Which of the following is the most appropriate treatment plan?

  1. Pulse steroids followed by oral steroids with no additional immunosuppression

  2. Pulse steroids followed by oral steroids and initiation of intravenous cyclophosphamide

  3. Pulse steroids followed by oral steroids and plasmapheresis

  4. Pulse steroids followed by oral steroids, plasmapheresis, and initiation of intravenous cyclophosphamide

  5. Supportive care alone without immunosuppression given the patient’s advanced age

Discussion of Question 2B

Of the four treatment choices offered, the regimen of pulse steroids followed by oral steroids and initiation of cyclophosphamide is the regimen supported by both Kidney Disease Outcomes Quality Initiative and Kidney Disease Improving Global Outcomes in practice guidelines for treating ANCA-associated GN (21,22) (choice B is correct) (Figure 6). The guidelines do not specifically endorse intravenous versus oral cyclophosphamide. A randomized clinical trial conducted in 42 centers in 12 European countries showed similar efficacy between these regimens, with reduced cumulative doses and lower rates of neutropenia using an intravenous regimen (25). However, a subsequent report with the long-term follow-up data from this trial cited significantly higher relapse rates in subjects treated with intravenous cyclophosphamide (39.5%) than in those treated with oral cyclophosphamide (20.8%) (26). The dose of cyclophosphamide (whether administered by the oral or intravenous route) would need to be significantly reduced in this setting given this patient’s advanced age and impaired renal function.

Figure 6.
Figure 6.

Answer for case 2, question 2B: Which of the following is the most appropriate treatment plan? The correct answer is B.

Plasmapheresis (choices C and D) would not be indicated in this patient given the absence of pulmonary hemorrhage and/or severe renal failure, which is defined as serum creatinine >500 µmol/L (5.8 mg/dl) or need for hemodialysis. In small, retrospective case series without controls, plasmapheresis has been shown to reduce mortality in patients with ANCA-associated GN and diffuse alveolar hemorrhage (27,28). Although these data are not particularly robust, the paucity of additional treatment options and the consequences of not treating in a disease with high mortality have overshadowed the shortcomings of the supportive evidence. In contrast, the data supporting the use of plasmapheresis for severe kidney failure caused by ANCA-associated GN stem from a randomized, multicenter trial of 137 patients (29). The Plasma Exchange for Renal Vasculitis (MEPEX) Trial, performed by the European Vasculitis Study Group, found that patients who received plasmapheresis had a significantly greater chance of being alive and dialysis independent at 3 (primary end point) and 12 (secondary end point) months compared with patients who did not receive plasmapheresis. Notably, this effect was essentially mediated by reduced rates of ESRD at 1 year (19% with plasmapheresis versus 43% without plasmapheresis), because overall survival between the groups was similar (73% versus 76%, respectively). A report on the long-term follow-up (approximately 4 years) of the patients from the MEPEX Study (30) likewise showed that rates of ESRD were lower in patients who received plasmapheresis (33% versus 49%, respectively), but overall mortality was similarly high (51% for both groups) over the follow-up period.

Finally, previous reports examining the course of ANCA-associated pauci-immune GN in the elderly (usually defined as 65 years of age and older) have highlighted a particularly poor prognosis for older patients, with significantly higher rates of death, ESRD, and treatment-related complications than their younger counterparts (31–33). Very elderly patients (age ≥80 years old), such as this patient, would be expected to experience even worse outcomes. However, in a retrospective cohort study of patients ≥80 years of age with ANCA-associated pauci-immune GN, the use of immunosuppressive therapy significantly reduced the risk for ESRD, death, and the combined outcome of ESRD or death. The benefit of immunosuppressive therapy was experienced early (within the first 6 months of diagnosis) in the form of reduced risk for ESRD and later (after 1 year) in the form of prolonged survival and in particular, prolonged dialysis-free survival. Receiver operating characteristic curve analysis suggested that this benefit could be expected most in very elderly patients who presented with a creatinine of 4.5 mg/dl or lower (34). Hence, this patient should be offered immunosuppression, particularly in light of his excellent functional status and his presenting creatinine well below 4.5 mg/dl.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

References

  1. ↵
    1. Glassock RJ
    : Secondary membranous glomerulonephritis. Nephrol Dial Transplant 7[Suppl 1]: 64–71, 1992pmid:1337185
    OpenUrlPubMed
  2. ↵
    1. Markowitz GS
    : Membranous glomerulopathy: Emphasis on secondary forms and disease variants. Adv Anat Pathol 8: 119–125, 2001pmid:11345236
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lefaucheur C,
    2. Stengel B,
    3. Nochy D,
    4. Martel P,
    5. Hill GS,
    6. Jacquot C,
    7. Rossert J,
    8. GN-PROGRESS Study Group
    : Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 70: 1510–1517, 2006pmid:16941021
    OpenUrlCrossRefPubMed
  4. ↵
    1. Beck LH Jr..,
    2. Bonegio RG,
    3. Lambeau G,
    4. Beck DM,
    5. Powell DW,
    6. Cummins TD,
    7. Klein JB,
    8. Salant DJ
    : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11–21, 2009pmid:19571279
    OpenUrlCrossRefPubMed
  5. ↵
    1. Qin W,
    2. Beck LH Jr..,
    3. Zeng C,
    4. Chen Z,
    5. Li S,
    6. Zuo K,
    7. Salant DJ,
    8. Liu Z
    : Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137–1143, 2011pmid:21566055
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Debiec H,
    2. Nauta J,
    3. Coulet F,
    4. van der Burg M,
    5. Guigonis V,
    6. Schurmans T,
    7. de Heer E,
    8. Soubrier F,
    9. Janssen F,
    10. Ronco P
    : Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 364: 1252–1259, 2004pmid:15464186
    OpenUrlCrossRefPubMed
    1. Murtas C,
    2. Bruschi M,
    3. Candiano G,
    4. Moroni G,
    5. Magistroni R,
    6. Magnano A,
    7. Bruno F,
    8. Radice A,
    9. Furci L,
    10. Argentiero L,
    11. Carnevali ML,
    12. Messa P,
    13. Scolari F,
    14. Sinico RA,
    15. Gesualdo L,
    16. Fervenza FC,
    17. Allegri L,
    18. Ravani P,
    19. Ghiggeri GM
    : Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 7: 1394–1400, 2012pmid:22773590
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Tomas NM,
    2. Beck LH Jr..,
    3. Meyer-Schwesinger C,
    4. Seitz-Polski B,
    5. Ma H,
    6. Zahner G,
    7. Dolla G,
    8. Hoxha E,
    9. Helmchen U,
    10. Dabert-Gay AS,
    11. Debayle D,
    12. Merchant M,
    13. Klein J,
    14. Salant DJ,
    15. Stahl RA,
    16. Lambeau G
    : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 371: 2277–2287, 2014pmid:25394321
    OpenUrlCrossRefPubMed
  9. ↵
    1. Stanescu HC,
    2. Arcos-Burgos M,
    3. Medlar A,
    4. Bockenhauer D,
    5. Kottgen A,
    6. Dragomirescu L,
    7. Voinescu C,
    8. Patel N,
    9. Pearce K,
    10. Hubank M,
    11. Stephens HA,
    12. Laundy V,
    13. Padmanabhan S,
    14. Zawadzka A,
    15. Hofstra JM,
    16. Coenen MJ,
    17. den Heijer M,
    18. Kiemeney LA,
    19. Bacq-Daian D,
    20. Stengel B,
    21. Powis SH,
    22. Brenchley P,
    23. Feehally J,
    24. Rees AJ,
    25. Debiec H,
    26. Wetzels JF,
    27. Ronco P,
    28. Mathieson PW,
    29. Kleta R
    : Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616–626, 2011pmid:21323541
    OpenUrlCrossRefPubMed
  10. ↵
    1. Glassock RJ
    : The pathogenesis of membranous nephropathy: Evolution and revolution. Curr Opin Nephrol Hypertens 21: 235–242, 2012pmid:22388552
    OpenUrlCrossRefPubMed
  11. ↵
    1. Debiec H,
    2. Ronco P
    : PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 364: 689–690, 2011pmid:21323563
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hoxha E,
    2. Kneißler U,
    3. Stege G,
    4. Zahner G,
    5. Thiele I,
    6. Panzer U,
    7. Harendza S,
    8. Helmchen UM,
    9. Stahl RA
    : Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 82: 797–804, 2012pmid:22673885
    OpenUrlCrossRefPubMed
  13. ↵
    1. Glassock RJ
    : Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: A new personalized medical approach. Clin J Am Soc Nephrol 9: 1341–1343, 2014pmid:25035274
    OpenUrlFREE Full Text
  14. ↵
    1. Messias NC,
    2. Silva FG,
    3. Messias E,
    4. Walker PD
    1. Larsen CP
    ,Messias NC, Silva FG, Messias E, Walker PD: Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 26: 709–715, 2013
    OpenUrlCrossRefPubMed
  15. ↵
    1. Orth SR,
    2. Ritz E
    : The nephrotic syndrome. N Engl J Med 338: 1202–1211, 1998pmid:9554862
    OpenUrlCrossRefPubMed
  16. ↵
    1. Barbour SJ,
    2. Greenwald A,
    3. Djurdjev O,
    4. Levin A,
    5. Hladunewich MA,
    6. Nachman PH,
    7. Hogan SL,
    8. Cattran DC,
    9. Reich HN
    : Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 81: 190–195, 2012pmid:21918501
    OpenUrlCrossRefPubMed
  17. ↵
    1. Lionaki S,
    2. Derebail VK,
    3. Hogan SL,
    4. Barbour S,
    5. Lee T,
    6. Hladunewich M,
    7. Greenwald A,
    8. Hu Y,
    9. Jennette CE,
    10. Jennette JC,
    11. Falk RJ,
    12. Cattran DC,
    13. Nachman PH,
    14. Reich HN
    : Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43–51, 2012pmid:22076873
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Lee T,
    2. Biddle AK,
    3. Lionaki S,
    4. Derebail VK,
    5. Barbour SJ,
    6. Tannous S,
    7. Hladunewich MA,
    8. Hu Y,
    9. Poulton CJ,
    10. Mahoney SL,
    11. Charles Jennette J,
    12. Hogan SL,
    13. Falk RJ,
    14. Cattran DC,
    15. Reich HN,
    16. Nachman PH
    : Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 85: 1412–1420, 2014pmid:24336031
    OpenUrlCrossRefPubMed
  19. ↵
    1. Medjeral-Thomas N,
    2. Ziaj S,
    3. Condon M,
    4. Galliford J,
    5. Levy J,
    6. Cairns T,
    7. Griffith M
    : Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 9: 478–483, 2014pmid:24334865
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Polanco N,
    2. Gutiérrez E,
    3. Covarsí A,
    4. Ariza F,
    5. Carreño A,
    6. Vigil A,
    7. Baltar J,
    8. Fernández-Fresnedo G,
    9. Martín C,
    10. Pons S,
    11. Lorenzo D,
    12. Bernis C,
    13. Arrizabalaga P,
    14. Fernández-Juárez G,
    15. Barrio V,
    16. Sierra M,
    17. Castellanos I,
    18. Espinosa M,
    19. Rivera F,
    20. Oliet A,
    21. Fernández-Vega F,
    22. Praga M,
    23. Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología
    : Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697–704, 2010pmid:20110379
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Radhakrishnan J,
    2. Cattran DC
    : The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines—application to the individual patient. Kidney Int 82: 840–856, 2012pmid:22895519
    OpenUrlCrossRefPubMed
  22. ↵
    1. Beck L,
    2. Bomback AS,
    3. Choi MJ,
    4. Holzman LB,
    5. Langford C,
    6. Mariani LH,
    7. Somers MJ,
    8. Trachtman H,
    9. Waldman M
    : KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 62: 403–441, 2013pmid:23871408
    OpenUrlCrossRefPubMed
  23. ↵
    1. Moutzouris DA,
    2. Herlitz L,
    3. Appel GB,
    4. Markowitz GS,
    5. Freudenthal B,
    6. Radhakrishnan J,
    7. D’Agati VD
    : Renal biopsy in the very elderly. Clin J Am Soc Nephrol 4: 1073–1082, 2009pmid:19443626
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Bomback AS,
    2. Herlitz LC,
    3. Markowitz GS
    : Renal biopsy in the elderly and very elderly: Useful or not? Adv Chronic Kidney Dis 19: 61–67, 2012pmid:22449342
    OpenUrlCrossRefPubMed
  25. ↵
    1. de Groot K,
    2. Harper L,
    3. Jayne DR,
    4. Flores Suarez LF,
    5. Gregorini G,
    6. Gross WL,
    7. Luqmani R,
    8. Pusey CD,
    9. Rasmussen N,
    10. Sinico RA,
    11. Tesar V,
    12. Vanhille P,
    13. Westman K,
    14. Savage CO,
    15. EUVAS (European Vasculitis Study Group)
    : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 150: 670–680, 2009pmid:19451574
    OpenUrlCrossRefPubMed
  26. ↵
    1. Harper L,
    2. Morgan MD,
    3. Walsh M,
    4. Hoglund P,
    5. Westman K,
    6. Flossmann O,
    7. Tesar V,
    8. Vanhille P,
    9. de Groot K,
    10. Luqmani R,
    11. Flores-Suarez LF,
    12. Watts R,
    13. Pusey C,
    14. Bruchfeld A,
    15. Rasmussen N,
    16. Blockmans D,
    17. Savage CO,
    18. Jayne D,
    19. EUVAS investigators
    : Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955–960, 2012pmid:22128076
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lauque D,
    2. Cadranel J,
    3. Lazor R,
    4. Pourrat J,
    5. Ronco P,
    6. Guillevin L,
    7. Cordier JF
    : Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine (Baltimore) 79: 222–233, 2000pmid:10941351
    OpenUrlCrossRefPubMed
  28. ↵
    1. Klemmer PJ,
    2. Chalermskulrat W,
    3. Reif MS,
    4. Hogan SL,
    5. Henke DC,
    6. Falk RJ
    : Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42: 1149–1153, 2003pmid:14655185
    OpenUrlCrossRefPubMed
  29. ↵
    1. Jayne DR,
    2. Gaskin G,
    3. Rasmussen N,
    4. Abramowicz D,
    5. Ferrario F,
    6. Guillevin L,
    7. Mirapeix E,
    8. Savage CO,
    9. Sinico RA,
    10. Stegeman CA,
    11. Westman KW,
    12. van der Woude FJ,
    13. de Lind van Wijngaarden RA,
    14. Pusey CD,
    15. European Vasculitis Study Group
    : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–2188, 2007pmid:17582159
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Walsh M,
    2. Casian A,
    3. Flossmann O,
    4. Westman K,
    5. Höglund P,
    6. Pusey C,
    7. Jayne DR,
    8. European Vasculitis Study Group (EUVAS)
    : Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84: 397–402, 2013pmid:23615499
    OpenUrlCrossRefPubMed
  31. ↵
    1. Harper L,
    2. Savage CO
    : ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology (Oxford) 44: 495–501, 2005pmid:15613403
    OpenUrlCrossRefPubMed
    1. Kaplan-Pavlovcic S,
    2. Cerk K,
    3. Kveder R,
    4. Lindic J,
    5. Vizjak A
    : Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18[Suppl 5]: v5–v7, 2003pmid:12817057
    OpenUrlCrossRefPubMed
  33. ↵
    1. Chen M,
    2. Yu F,
    3. Zhang Y,
    4. Zhao MH
    : Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87: 203–209, 2008pmid:18626303
    OpenUrlCrossRefPubMed
  34. ↵
    1. Bomback AS,
    2. Appel GB,
    3. Radhakrishnan J,
    4. Shirazian S,
    5. Herlitz LC,
    6. Stokes B,
    7. D’Agati VD,
    8. Markowitz GS
    : ANCA-associated glomerulonephritis in the very elderly. Kidney Int 79: 757–764, 2011pmid:21160463
    OpenUrlCrossRefPubMed
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
American Society of Nephrology Quiz and Questionnaire 2014: Glomerular Diseases
Andrew S. Bomback, Mark A. Perazella, Michael J. Choi
CJASN Apr 2015, 10 (4) 716-722; DOI: 10.2215/CJN.11821214
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords